Preparation of recombinant human canstatin using transgenic Dunaliella safina  

作　　者：Shuying Feng Sanqiang Li Qinghua Li Ke Shi Lexun Xue 

机构地区：[1]Department of Immunology, Medical College, Henan University of Science and Technology, Luoyang 471003, China [2]Laboratory for Cell Biology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China

出　　处：《Acta Biochimica et Biophysica Sinica》2014年第5期428-430,共3页生物化学与生物物理学报（英文版）

基　　金：This work was supported by the grants from International Science and Technology Cooperation Program of Ministry of Science and Technology of China （No. 2007DFA01240）, the National Natural Science Foundation of China （No. 30900796）, and the Doctor＇s Research Initial Fund of Henan University of Science and Technology （No. 09001413）.

摘　　要：Canstatin, which possesses a significant inhibition effect on the migration of endothelial cells and a strong anticancer effect [1,2], has been applied in the treatment of many cancers including human oral, breast, prostate, pancreatic, and colorectal [3-7]. However, because the expression of bioactive recombinant canstatin is very low using the current expression systems, e.g. prokaryotic Escherichia coli expression system [6], its application has still been limited to clinical trials. Several eukaryotic cell expression systems have been exploited for canstatin production, such as Bombyx mori cells [8] and Drosophila melanogaster S2 cells [9], but they also have a lot of disadvantages, for example, high culture cost, poor yield, and difficulty in purification. Therefore, it is necessary and urgent to develop an optimal expression system for the large-scale production of the recombinant canstatin.Canstatin, which possesses a significant inhibition effect on the migration of endothelial cells and a strong anticancer effect [1,2], has been applied in the treatment of many cancers including human oral, breast, prostate, pancreatic, and colorectal [3-7]. However, because the expression of bioactive recombinant canstatin is very low using the current expression systems, e.g. prokaryotic Escherichia coli expression system [6], its application has still been limited to clinical trials. Several eukaryotic cell expression systems have been exploited for canstatin production, such as Bombyx mori cells [8] and Drosophila melanogaster S2 cells [9], but they also have a lot of disadvantages, for example, high culture cost, poor yield, and difficulty in purification. Therefore, it is necessary and urgent to develop an optimal expression system for the large-scale production of the recombinant canstatin.

分 类 号：Q463[生物学—生理学] TG335.71[金属学及工艺—金属压力加工]